KAICO Co., Ltd., a venture from Kyushu University, has applied for a patent on oral vaccines in collaboration with Kyushu University and Kagoshima University.In the future, we will maximize the resources of both schools and promote the development of oral vaccines against the new coronavirus.
According to KAICO, most of the vaccines currently in use are inoculated by injection at medical institutions, and securing medical staff and establishing an inoculation site are issues.If an oral vaccine is developed, anyone can inoculate it at home as if taking a supplement, and problems such as securing medical staff will be solved.
KAICO applied for a patent in collaboration with Associate Professor Ken Miyata, who is working on the development of an oral vaccine by examining the molecular design of antigenic proteins and vaccine administration methods at the Faculty of Agriculture, Kagoshima University.Using this technology, we aim to commercialize an oral vaccine for livestock prior to human use.
Many vaccines have restrictions in terms of temperature control, but KAICO will develop a vaccine that can be stored at room temperature, and will also solve problems in terms of transportation and storage at the same time.
KAICO was established in 2018 with the aim of developing drugs, diagnostics and reagents for difficult-to-express proteins.The core technology is recombinant protein expression using silkworm, which is being researched by Professor Yoshihiro Kusakabe of the Faculty of Agriculture, Kyushu University. I'm out.
